Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person UniProt:P01100-2 FOS
| Class:Id | ReferenceIsoform:8971440 |
|---|---|
| _chainChangeLog | chain:1-380 added on Fri February 17 2017 |
| _displayName | UniProt:P01100-2 FOS |
| _timestamp | 2025-08-15 21:30:09 |
| chain | chain:1-380 |
| checksum | 9E3B2969347C90C8 |
| comment | FUNCTION Nuclear phosphoprotein which forms a tight but non-covalently linked complex with the JUN/AP-1 transcription factor. In the heterodimer, FOS and JUN/AP-1 basic regions each seems to interact with symmetrical DNA half sites. On TGF-beta activation, forms a multimeric SMAD3/SMAD4/JUN/FOS complex at the AP1/SMAD-binding site to regulate TGF-beta-mediated signaling. Has a critical function in regulating the development of cells destined to form and maintain the skeleton. It is thought to have an important role in signal transduction, cell proliferation and differentiation. In growing cells, activates phospholipid synthesis, possibly by activating CDS1 and PI4K2A. This activity requires Tyr-dephosphorylation and association with the endoplasmic reticulum.SUBUNIT Heterodimer; with JUN (By similarity). Component of the SMAD3/SMAD4/JUN/FOS complex required for synergistic TGF-beta-mediated transcription at the AP1 promoter site (PubMed:9732876). Interacts with SMAD3; the interaction is weak even on TGF-beta activation (PubMed:9732876). Interacts with MAFB (By similarity). Interacts with TSC22D3 (via N-terminus); this interaction inhibits the binding of active AP1 to its target DNA (By similarity). Interacts with CDS1 and PI4K2A (By similarity). Interacts (via bZIP domain and leucine-zipper region) with the multiprotein chromatin-remodeling complexes SWI/SNF: SWI/SNF-A (BAF) subunits SMARCB1, SMARCC2 and SMARCD1 (By similarity). Interacts (via bZIP domain and leucine-zipper region) with ARID1A (By similarity).INTERACTION In quiescent cells, present in very small amounts in the cytosol. Following induction of cell growth, first localizes to the endoplasmic reticulum and only later to the nucleus. Localization at the endoplasmic reticulum requires dephosphorylation at Tyr-10 and Tyr-30.ALTERNATIVE PRODUCTS Expressed at very low levels in quiescent cells. When cells are stimulated to reenter growth, they undergo 2 waves of expression, the first one peaks 7.5 minutes following FBS induction. At this stage, the protein is localized endoplasmic reticulum. The second wave of expression occurs at about 20 minutes after induction and peaks at 1 hour. At this stage, the protein becomes nuclear.PTM Phosphorylated in the C-terminal upon stimulation by nerve growth factor (NGF) and epidermal growth factor (EGF). Phosphorylated, in vitro, by MAPK and RSK1. Phosphorylation on both Ser-362 and Ser-374 by MAPK1/2 and RSK1/2 leads to protein stabilization with phosphorylation on Ser-374 being the major site for protein stabilization on NGF stimulation. Phosphorylation on Ser-362 and Ser-374 primes further phosphorylations on Thr-325 and Thr-331 through promoting docking of MAPK to the DEF domain. Phosphorylation on Thr-232, induced by HA-RAS, activates the transcriptional activity and antagonizes sumoylation. Phosphorylation on Ser-362 by RSK2 in osteoblasts contributes to osteoblast transformation (By similarity).PTM Constitutively sumoylated with SUMO1, SUMO2 and SUMO3. Desumoylated by SENP2. Sumoylation requires heterodimerization with JUN and is enhanced by mitogen stimulation. Sumoylation inhibits the AP-1 transcriptional activity and is, itself, inhibited by Ras-activated phosphorylation on Thr-232.PTM In quiescent cells, the small amount of FOS present is phosphorylated at Tyr-10 and Tyr-30 by SRC. This Tyr-phosphorylated form is cytosolic. In growing cells, dephosphorylated by PTPN2. Dephosphorylation leads to the association with endoplasmic reticulum membranes and activation of phospholipid synthesis.SIMILARITY Belongs to the bZIP family. Fos subfamily. |
| created | [InstanceEdit:8964659] Weiser, JD |
| description | recommendedName: fullName evidence="14"Protein c-Fos alternativeName: Cellular oncogene fos alternativeName: fullName evidence="15"Fos proto-oncogene, AP-1 transcription factor subunit alternativeName: G0/G1 switch regulatory protein 7 alternativeName: Proto-oncogene c-Fos alternativeName: fullName evidence="14"Transcription factor AP-1 subunit c-Fos |
| geneName | FOS G0S7 |
| identifier | P01100 |
| isoformParent | |
| isSequenceChanged | FALSE |
| keyword | 3D-structure Alternative splicing Cytoplasm DNA-binding Endoplasmic reticulum Isopeptide bond Nucleus Phosphoprotein Proteomics identification Proto-oncogene Reference proteome Ubl conjugation |
| modified | [InstanceEdit:9836292] Weiser, Joel, 2023-05-25 [InstanceEdit:9852000] Weiser, Joel, 2023-11-03 [InstanceEdit:9926675] Weiser, Joel, 2024-11-03 [InstanceEdit:9963647] Weiser, Joel, 2025-08-15 |
| name | FOS |
| referenceDatabase | [ReferenceDatabase:2] UniProt |
| referenceGene | [ReferenceDNASequence:8878309] ENSEMBL:ENSG00000170345 FOS [Homo sapiens] |
| secondaryIdentifier | FOS_HUMAN A8K4E2 B4DQ65 P18849 |
| sequenceLength | 380 |
| species | [Species:48887] Homo sapiens |
| variantIdentifier | P01100-2 |
| [Change default viewing format] | |
No pathways have been reviewed or authored by UniProt:P01100-2 FOS (8971440)
